CAG方案治疗老年急性髓系白血病和骨髓增生异常综合征的疗效进展

Progress in the Efficacy of CAG Regimen for Elderly Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

急性髓系白血病(AML)是一种造血干细胞疾病,发生于各个年龄阶段,常见于老年患者(年龄≥60岁),其最佳的治疗手段仍存在争议。予以强化化疗的老年AML患者较年轻患者,具有更高的病死率和更低的完全缓解率。同时,由于骨髓增生异常综合征(MDS)患者中有相当一部分人最终会转化为AML,因此治疗具有相关性。而年龄和合并疾病是影响两类患者治疗方案选择的两大自身因素,故强化化疗常难以实施,且化疗引起的骨髓抑制恢复时间较慢。目前,这两类患者的治疗是难点。因此,对于化疗方案的选择尤为重要。CAG方案具有化疗强度温和、敏感性好、完全缓解率及有效率高、不良反应小等优点。通过研究其在治疗老年AML和MDS方面的新进展,以期为临床应用及治疗提供一定的参考和帮助。

Acute myeloid leukemia（ AML） is a hematopoietic stem cell disorder which may occur at all ages. It is primarily a disease of older adults（ age ≥60 years old）,for whom optimal treatment strategies remain controverisal. Elderly AML patients treated with intensive chemotherapy have a higher mortality rate and a lower rate of complete remission compared with the younger population. Meanwhile,a considerable portion of people of the myelodysplastic syndrome（ MDS） patients may eventually develop into AML,so the treatments are relative. As age and complicated disease are the two major factors that affect the choice of treatment options for the two types of patients,intensive chemotherapy is often difficult to implement and the recovery time of bone marrow suppression caused by chemotherapy is slow. Currently,the treatment of the two types of patients is difficult. Therefore,the choice of chemotherapy regimen is especially important. The CAG regimen has the advantages of high complete remission rate and efficacy,few adverse effects,which is expected to provide some reference and help to the clinical application and treatmen through its new progress in the treatment of elderly AML and MDS.